Lumida
/STOK
⌘K
Stoke Therapeutics Inc

Stoke Therapeutics Inc

STOK
$29.03USD↓-1.06%-0.31 today

MARKET CAP

1.9B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$29 – $30

52W RANGE

$20
$40

AI Summary

Stalk
Sell NowHigh

STOK is entrenched in a Stage 4 decline following a high-volume support failure beneath the 29.65 zone, confirming a new downtrend with lower highs and lower lows under declining EMAs. Medium-term bias remains bearish as price trades below the 9/20/50 EMA cluster, and short-term bounces into the 30.00 6.00 6031.00 zone have been rejected, with momentum still negative and no mean-reversion eligibility. The optimal engagement is to sell now into structural resistance on any rally.

  • ↑74% convulsive seizure reduction in interim Zoriva-Nursen trials
  • ↑$411M cash runway into 2028 ensures Phase III funding
  • ↓Net loss of $38.3M in Q3 elevates cash burn risk
Full analysis →

Buying

4

institutions

Selling

6

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY5.88 M192.31 M+491.64 K+9.7%0.00%
TR

T. Rowe Price Investment Management, Inc.

Q2 2026

BUY2.42 M79.02 M+2.16 M+867.3%0.05%
JH

Janus Henderson Group Plc

Q1 2026

BUY1.63 M53.07 M+180.75 K+15.3%0.01%
CA

Citadel Advisors LLC

Q2 2026

BUY499.30 K16.34 M+319.88 K+179.7%0.00%
MM

Millennium Management LLC

Q2 2026

SELL261.03 K8.54 M+-251.11 K-48.8%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL259.35 K8.48 M+-6.12 K+0.6%0.00%
WP

Woodline Partners LP

Q2 2026

SELL50.12 K1.64 M+-50.12 K-49.8%0.01%
HS

Hussman Strategic Advisors, Inc.

Q2 2026

SELL42.00 K1.37 M+-42.00 K-49.8%0.32%
AC

Aqr Capital Management LLC

Q2 2026

SELL26.45 K865.41 K+-20.01 K-42.8%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL19.94 K652.40 K+-3.94 K-16.1%0.00%